

# Schrödinger Receives Milestone Payment from Sanofi Collaboration

7/11/2019

Milestone marks advancement of second drug discovery program under the collaboration

NEW YORK – July 11, 2019 - Schrödinger today announced receipt of a preclinical milestone payment from **Sanofi** in a drug discovery program advancing as part of a multi-year, multi-target collaboration between the two companies.

Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate. Earlier this spring, Schrödinger announced the advancement of a separate program in autoimmune disease into clinical trials.

“This is an especially exciting moment in our collaboration with Sanofi as it marks another program advanced,” said Karen Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist. “Achieving this milestone is a testament to the value of our ongoing collaboration with partners and our ability to efficiently identify promising therapeutic compounds.”

The work with Sanofi is one of several collaborations Schrödinger has established with leading biotech and pharmaceutical companies around the world. These collaborations leverage Schrödinger’s physics-based computational platform to enable rapid iterations of design and analysis of potential therapeutic compounds. Such collaborations have already led to several clinical-stage assets and two FDA-approved oncology drugs. More than two dozen **additional programs** are moving through discovery and development in indications including oncology, diabetes, metabolic disorders, schizophrenia, and neurodegenerative diseases.

[About Schrödinger](#)

Schrödinger's industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide. In addition to this substantial and growing global business, Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger's significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit [schrodinger.com](http://schrodinger.com) for more information.

Media Contact:

Stephanie Simon

**[stephanie@tenbridgecommunications.com](mailto:stephanie@tenbridgecommunications.com)**

617-581-9333

Investor Contact:

Christina Tartaglia

Stern IR, Inc.

**[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)**

212-362-1200